Emily Menendez

GU Oncology Now

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC), as it has a low <a href="https://academic.oup.com/oncolo/article/27/12/e957/6775137" target="_blank" rel="noopener">toxicity profile</a> and yields high prostate-specific antigen (PSA) responses. While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages are likely to benefit from [177Lu]Lu-PSMA (177Lu-PSMA)- or [225Ac]Ac-PSMA (225Ac-PSMA)-radioligand treatment. A new <a href="https://www.mdpi.com/2072-6694/15/1/297" target="_blank" rel="noopener">retrospective study</a> analyzed the safety and efficacy or PSMA-RLT in patients with early-stage and hormone-sensitive metastatic prostate cancer.The study comprised patients with early-stage metastatic prostate cancer who had been treated with 177Lu-PSMA and/or 225Ac-PSMA previously. Of the 20 patients included in the study, 18 received 177Lu-PSMA-radioligand treatment and 2 received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands.The primary outcome of the study was progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcomes were PSA response and date of onset of CRPC state. Patients received a median of 2 treatment cycles (range, 1-6 cycles) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range, 5.2-7.4 GBq).PSMA-RLT treatment was well-tolerated overall in the patient group. The most common grade 1-2 side effects were dry mouth (n=6) and fatigue (n=8), which were only temporarily reported. One patient who received 225Ac-PSMA developed grade 3-4 bone marrow toxicity, and 1 patient developed CRPC 9 months following PSMA-RLT. The median PFS was 12 months (95% CI, 4.09-19.90 months). A total of 17 (85%) patients had a &ge;50% PSA response after PSMA-RLT treatment.This small cohort study demonstrated the safety and efficacy of PSMA-RLT treatment for patients with metastasized early-stage and hormone-sensitive prostate cancer. Additional studies should be carried out using larger cohorts and long-term follow-up to further investigate these findings.

Safety and Efficacy of PSMA-RLT in Early-Stage and Hormone-Sensitive Prostate Cancer

Radioligand therapy prostate-specific membrane antigen

While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages are likely to benefit from radioligand treatment.

Safety, Efficacy of PSMA-RLT in Early-Stage Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe